Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 1.00 |
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | LCK | P06239 | 10/20 | 1.00 |
| ▸ | ITK | Q08881 | 8/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410335 | 1.00 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL441651 | 1.00 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL441652 | 1.00 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL459846 | 1.00 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL459847 | 1.00 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL18123609 | 0.88 | BTK (0.79) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL18123636 | 0.88 | BTK (0.79) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL18123604 | 0.87 | BTK (0.80) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL18123620 | 0.87 | BTK (0.80) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL17329278 | 0.87 | BTK (0.77) | BTKEGFRLCKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152115-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-04 | — | — | US | claimed |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | claimed |
| US-20120277255-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | claimed |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | claimed |
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | TELIOS PHARMA INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250064805-A1 | Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate | TELIOS PHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240317756-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240293403-A1 | Treatment of Symptoms Associated with Myeloproliferative Neoplasms | TELIOS PHARMA, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | TELIOS PHARMA, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023137182-A1 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS BASED ON BTK OCCUPANCY & RESYNTHESIS RATE | TELIOS PHARMA INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20120277255-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120202264-A1 | INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE | PHARMACYCLICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277255-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, KIT, LYN | BTK 1/4885EGFR 262/4885LCK 10/4885 |
| US-20240293403-A1 | Treatment of Symptoms Associated with Myeloproliferative Neoplasms | ABL1, BTK, JAK2 | BTK 2/4885EGFR 553/4885LCK 13/4885 |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | BTK, LYN, ABL1 | BTK 1/4885EGFR 935/4885LCK 5/4885 |
| US-20240000782-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | BTK, SYK, LCK | BTK 1/4885EGFR 812/4885LCK 3/4885 |
| US-20240317756-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20150152115-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | BTK 1/4885EGFR 497/4885LCK 8/4885 |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, LYN, ABL1 | BTK 1/4885EGFR 935/4885LCK 5/4885 |
| US-20250064805-A1 | Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate | BTK, ABL1, MPL | BTK 1/4885EGFR 489/4885LCK 8/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.